Scarica l'app Stockscreener
2.06
0.98%
0.02
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$2.04
Aprire:
$2.09
Volume 24 ore:
21,693
Relative Volume:
0.57
Capitalizzazione di mercato:
$23.84M
Reddito:
$3.35M
Utile/perdita netta:
$86,000
Rapporto P/E:
133.77
EPS:
0.0154
Flusso di cassa netto:
$2.67M
1 W Prestazione:
+3.00%
1M Prestazione:
-9.25%
6M Prestazione:
-7.62%
1 anno Prestazione:
+79.13%
Intervallo 1D:
$2.02
$2.09
Intervallo di 1 settimana:
$1.91
$2.09
Portata 52W:
$0.99
$2.95
Therapeuticsmd Inc Stock (TXMD) Company Profile
Nome
Therapeuticsmd Inc
Settore
Telefono
561-961-1900
Indirizzo
951 YAMATO ROAD, SUITE 220, BOCA RATON, FL
Compare TXMD vs TAK, HLN, TEVA, ZTS, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TXMD
Therapeuticsmd Inc
|
2.06 | 23.61M | 3.35M | 86,000 | 2.67M | 0.0154 |
TAK
Takeda Pharmaceutical Co Adr
|
17.15 | 53.43B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
10.10 | 44.52B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.03 | 37.52B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
76.56 | 32.24B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
535.67 | 22.46B | 3.17B | 1.29B | 1.01B | 27.09 |
Therapeuticsmd Inc Stock (TXMD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2020-08-07 | Downgrade | Jefferies | Hold → Underperform |
| 2020-05-19 | Downgrade | JP Morgan | Overweight → Neutral |
| 2019-12-02 | Iniziato | Guggenheim | Buy |
| 2019-10-17 | Iniziato | H.C. Wainwright | Buy |
| 2019-04-30 | Ripresa | Noble Capital Markets | Outperform |
| 2018-06-15 | Iniziato | JP Morgan | Overweight |
| 2017-09-08 | Iniziato | Morgan Stanley | Equal-Weight |
| 2017-07-11 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2017-05-09 | Downgrade | Oppenheimer | Outperform → Perform |
| 2016-11-22 | Ripresa | Jefferies | Buy |
| 2016-11-22 | Iniziato | Oppenheimer | Outperform |
| 2016-11-07 | Ripresa | Guggenheim | Buy |
| 2016-04-04 | Iniziato | Goldman | Buy |
| 2015-12-08 | Reiterato | Jefferies | Buy |
| 2015-12-08 | Reiterato | Stifel | Buy |
| 2015-09-21 | Reiterato | Jefferies | Buy |
| 2015-06-09 | Iniziato | Guggenheim | Buy |
| 2014-07-08 | Iniziato | FBR Capital | Outperform |
| 2014-04-17 | Reiterato | Noble Financial | Buy |
| 2014-01-28 | Reiterato | Noble Financial | Buy |
Mostra tutto
Therapeuticsmd Inc Borsa (TXMD) Ultime notizie
TherapeuticsMD Inc. stock outperforms competitors on strong trading day - MarketWatch
TherapeuticsMD Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
TherapeuticsMD Inc. stock underperforms Monday when compared to competitors - MarketWatch
TXMD Q3 2023 Earnings: Significant EPS Miss Amid Ongoing ChallengesEarnings Call Highlights - DonanımHaber
TherapeuticsMD (TXMD) News Flow - Moomoo
TherapeuticsMD Inc. stock underperforms Thursday when compared to competitors - MarketWatch
TherapeuticsMD Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
TherapeuticsMD (TXMD) Rallies 3.94% as Stock Approaches Key Resistance at $2.22Stop Run - dars.gov.et
TherapeuticsMD Inc. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch
Price to earnings forward of TherapeuticsMD, Inc. – NASDAQ:TXMD - TradingView
Enterprise value to revenue forward of TherapeuticsMD, Inc. – NASDAQ:TXMD - TradingView
TherapeuticsMD Inc (TXMD) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
TherapeuticsMD Inc (TXMD) Valuation: PE, PB & Fair Value Analysis - TradingKey
TherapeuticsMD Inc (TXMD) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
TherapeuticsMD Inc (TXMD) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
TherapeuticsMD Inc. stock underperforms Monday when compared to competitors despite daily gains - MarketWatch
TherapeuticsMD Inc (TXMD) Institutional Confidence - TradingKey
TherapeuticsMD Inc (TXMD) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
TherapeuticsMD Inc (TXMD) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
TherapeuticsMD Inc (TXMD) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TherapeuticsMD Inc (TXMD) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
TXMD Q3 2023 Earnings: EPS Misses Estimates Amid Continued Cash BurnNet Income Trends - newsline.com
TherapeuticsMD (TXMD) Gains 3.64%, Tests Resistance at $2.39High Low Breadth - newsline.com
TXMD Q3 2023 Earnings: EPS Misses Estimates Sharply, Yet Stock Surges 20.9%EPS Surprise History - newsline.com
TXMD Q3 2023 Earnings: Wider-than-Expected Loss Highlights Operational ChallengesProfit Inflection Point - newsline.com
TherapeuticsMD (TXMD) Nears Support Amid Modest Selling PressureIndex Put Call - newsline.com
TherapeuticsMD Inc. (TXMD) Gains Ground as Shares Push Toward Resistance ZoneAAII Neutral - newsline.com
TherapeuticsMD Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
TXMD Q3 2023 Earnings: Significant EPS Miss Highlights Ongoing ChallengesEarnings Quality Score - dars.gov.et
TXMDTherapeuticsMD Inc Stock Price and Quote - Finviz
TXMD Q3 2023 Earnings: Deep EPS Miss Overshadowed by Strategic ProgressNegative Surprise Momentum - newsline.com
TXMD Q3 2023 Earnings: Significant EPS Miss Amid Operational ChallengesTrough Earnings Signal - The Legal Advocate
TXMD Q3 2023 Earnings: Wider-Than-Expected Loss Amid Zero RevenuePositive Surprise Momentum - DonanımHaber
TXMD Q3 2023 Earnings: EPS Misses Estimates, Stock DeclinesPost-Earnings Drift - newsline.com
TXMD Q3 2023 Earnings: EPS Misses Estimates by Wide Margin Amidst Operational ChallengesSaaS Earnings Trends - dars.gov.et
TXMD Q3 2023 Earnings: A Significant EPS Miss Amid No Reported RevenueLow Growth Earnings - newsline.com
TherapeuticsMD (TXMD) Edges Higher as Support Holds Near $2.01Post-Earnings Moves - Newser
What TherapeuticsMD TXMD flagged as biggest challenges ahead Q3 2023 EPS Misses ViewsBanking Earnings Report - The Legal Advocate
TherapeuticsMD Announces First Quarter 2026 Financial Results - BioSpace
Therapeuticsmd Inc Azioni (TXMD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.50%
0.79%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):